Test characteristics for combining non‐invasive liver fibrosis staging modalities in individuals with Hepatitis C virus
Journal of Viral Hepatitis · 2024
DOI: 10.1111/jvh.13925 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Journal of Viral Hepatitis, 2024. Verfasst von Rachel L Epstein und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Section of Infectious Diseases, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Liver Cirrhosis, Elasticity Imaging Techniques. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Allergy and Infectious Diseases, NIDA NIH HHS, Charles A. King Trust.
Abstract (Originalsprache)
Non‐invasive methods have largely replaced biopsy to identify advanced fibrosis in hepatitis C virus (HCV). Guidelines vary regarding testing strategy to balance accuracy, costs and loss to follow‐up. Although individual test characteristics are well‐described, data comparing the accuracy of using two tests together are limited. We calculated combined test characteristics to determine the utility of combined strategies. This study synthesizes empirical data from fibrosis staging trials and the literature to estimate test characteristics for Fibrosis‐4 (FIB4), APRI or a commercial serum panel (FibroSure®), followed by transient elastography (TE) or FibroSure®. We simulated two testing strategies: (1) second test only for those with intermediate first test results (staged approach), and (2) second test for all. We summarized empiric data with multinomial distributions and used this to estimate test characteristics of each strategy on a simulated population of 10,000 individuals with 4.2% cirrhosis prevalence. Negative predictive value (NPV) for cirrhosis from a single test ranged from 98.2% (95% CB 97.6–98.8%) for FIB‐4 to 99.4% (95% CB 99.0–99.8%) for TE. Using a staged approach with TE second, sensitivity for cirrhosis rose to 93.3–96.9%, NPV to 99.7–99.8%, while PPV dropped to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Section of Infectious Diseases, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA.
- Department of Pediatrics, Section of Infectious Diseases, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA.
- Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts, USA.
- Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA.
- Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Ontario, Canada.
- Department of Hepatology, Beaujon Hospital, Assistance Publique-Hopitaux de Paris, Université Paris Cité, Clichy, France.
ORCID-Profile: Rachel L Epstein, Lynn E Taylor
Förderung
- National Institute of Allergy and Infectious Diseases
- NIDA NIH HHS
- Charles A. King Trust
- NIH HHS
- NIAID NIH HHS
- Patrick and Catherine Weldon Donaghue Medical Research Foundation
- National Institutes of Health
- National Institute on Drug Abuse
Zitieren
APA
Epstein, R. L., Buzzee, B., White, L. F., Feld, J. J., Castera, L., Sterling, R. K., Linas, B. P., & Taylor, L. E. (2024). Test characteristics for combining non‐invasive liver fibrosis staging modalities in individuals with Hepatitis C virus. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.13925
Vancouver
Epstein RL, Buzzee B, White LF, Feld JJ, Castera L, Sterling RK, et al. Test characteristics for combining non‐invasive liver fibrosis staging modalities in individuals with Hepatitis C virus. Journal of Viral Hepatitis. 2024. doi:10.1111/jvh.13925
BibTeX
@article{Epstein2024,
author = {Epstein, Rachel L and Buzzee, Benjamin and White, Laura F and Feld, Jordan J and Castera, Laurent and Sterling, Richard K and Linas, Benjamin P and Taylor, Lynn E},
title = {Test characteristics for combining non‐invasive liver fibrosis staging modalities in individuals with Hepatitis C virus},
journal = {Journal of Viral Hepatitis},
year = {2024},
doi = {10.1111/jvh.13925}
}
EUVIMED